Hepatotoxicity of metastatic colorectal cancer chemotherapy: Systematic review;Toxicité hépatique de la chimiothérapie du cancer colorectal métastatique: Revue de la littérature

Bulletin du Cancer

Volumn 97, Issue 5, 2010, Pages 559-569

  Baumgaertner, I ^a   Ratziu, V ^a   Vaillant, J C ^a   Hannoun, L ^a   Poynard, T ^a   Andre T ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Chemotherapy; Colorectal cancer; Hepatic surgery; Hepatotoxicity

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; COLORECTAL CANCER; DATA BASE; DIGESTIVE SYSTEM PERFORATION; HIGH RISK PATIENT; HUMAN; LIVER INJURY; LIVER METASTASIS; LIVER TOXICITY; MEDLINE; MORBIDITY; MULTIPLE CYCLE TREATMENT; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PROGNOSIS; REVIEW; SINUSOIDAL OBSTRUCTION SYNDROME; SURGICAL MORTALITY; SYSTEMATIC REVIEW; THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; FATTY LIVER; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; LIVER VEIN OBSTRUCTION; METASTASIS; PATHOLOGY; VASCULARIZATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FATTY LIVER; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 77953060383     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2010.1049     Document Type: Review

References (74)

1. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. IARC CancerBase no 5. Lyon, France : IARC Press, 2001.
2. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radio-frequency ablation and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239: 818-25; discussion 825-917
3. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235: 759-766 (Pubitemid 34547293)
4. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240: 438-47; discussion 447-450
5. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005; 241: 715-22, discussion 722-814
6. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994; 343: 1405-1410 (Pubitemid 24167517)
7. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990; 77: 1241-1246
8. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
9. Sugarbaker PH. Surgical decision making for large bowel cancer metastatic to the liver. Radiology 1990; 174: 621-626
10. Scheele J. Hepatectomy for liver metastases. Br J Surg 1993; 80: 274-276
11. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947
12. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047
13. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. Folfiri followed by Folfox-6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237
14. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914
15. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory al. N Engl J Med 2004; 351: 337-345
16. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417
17. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671
18. Folprecht, abstract ASCO 2009 CELIM study abstract 296.
19. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664
20. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342
21. Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 2008; 26: 5910-5917
22. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with Folfox-4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016
23. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-728
24. Peppercorn PD, Reznek RH, Wilson P, Slevin ML, Gupta RK. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 1998; 77: 2008-2011 (Pubitemid 28254648)
25. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol 1993; 11: 2386-2390 (Pubitemid 23353968)
26. Miyake K, Hayakawa K, Nishino M, Morimoto T, Mukaihara S. Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer. Acad Radiol 2005; 12: 722-727 (Pubitemid 40791088)
27. Behrns KE, Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 1998; 2: 292-298 (Pubitemid 128409616)
28. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000; 191: 38-46. (Pubitemid 30439557)
29. Gomez D, Malik HZ, Bonney GK, Wong V, Toogood GJ, Lodge JP, et al. Steatosis predicts postoperative morbidity following hepatic resection for colorectal metastasis. Br J Surg 2007; 94: 1395-1402 (Pubitemid 350144389)
30. Parikh AA, Gentner B, Wu TT, Curley SA, Ellis LM, Vauthey JN. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 2003; 7: 1082-1088 (Pubitemid 37526731)
31. Kooby DA, Fong Y, Suriawinata A, Gonen M, Allen PJ, Klimstra DS, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003; 7: 1034-1044 (Pubitemid 37524071)
32. Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006; 243: 1-7. (Pubitemid 43054046)
33. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15: 460-466
34. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-2072
35. Hui AM, Kawasaki S, Makuuchi M, Nakayama J, Ikegami T, Miyagawa S. Liver injury following normothermic ischemia in steatotic rat liver. Hepatology 1994; 20: 1287-1293 (Pubitemid 24323579)
36. Ratziu V, Tahiri M, Bonyhay L. [Nonalcoholic steatohepatitis]. Ann Endocrinol (Paris) 2005 ; 66: 1S71-80.
37. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845
38. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200: 843-845
39. Kandutsch S, Klinger M, Hacker S, Wrba F, Gruenberger B, Gruenberger T. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. Eur J Surg Oncol 2008; 34: 1231-1236
40. Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, Dufour P, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008; 247: 118-124
41. Wicherts DA. J Clin Oncol 2009; 27: 15S (Supplement, abstract 4097).
42. Aloia T, Sebagh M, Plasse M, Karam V, Levi F, Giacchetti S, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24: 4983-4990 (Pubitemid 46631400)
43. Tisman G, Mac Donald D, Shindell N, Reece E, Patel P, Honda N, et al. J clin oncol 2004; 22: 3202-3204
44. Arotçarena R, Calès V, Berthelémy P, Parent Y, Malet M, Etcharry F, et al. Gastroenterol Clin Biol 2006; 11: 1313-1316
45. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006; 33: S26-34.
46. Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007; 110: 2761-2767 (Pubitemid 350250347)
47. Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant Xelox/Folfox therapy of colorectal cancer liver metastases. Eur J Surg Oncol 2009; 35: 515-520
48. Reddy SK, Morse MA, Hurwitz HI, Bendell JC, Gan TJ, Hill SE, et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008; 206: 96-106. (Pubitemid 350267242)
49. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008; 26: 5254-5260
50. D'Angelica M, Kornprat P, Gonen M, Chung KY, Jarnagin WR, DeMatteo RP, et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 2007; 14: 759-765
51. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26: 1830-1835
52. Adam R. Postoperative liver function recovery after hepatic resection for colorectal metastases previously treated with bevacizumab. J Clin Oncol 27:15s, 2009 (suppl; abstr 4093).
53. Agarwal V, Sgouros J, Smithson J, Lodge J, Razack A, Campbell A, et al. Sinusoidal obstruction syndrome (veno-occlusive disease) in a patient receiving bevacizumab for metastatic colorectal cancer: a case report. J Med Case Reports 2008; 2: 227.
54. Laurent A, Nicco C, Chereau C, Goulvestre C, Alexandre J, Alves A, et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 2005; 65: 948-956
55. Shimizu H, Miyazaki M, Wakabayashi Y, Mitsuhashi N, Kato A, Ito H, et al. Vascular endothelial growth factor secreted by replicating hepatocytes induces sinusoidal endothelial cell proliferation during regeneration after partial hepatectomy in rats. J Hepatol 2001; 34: 683-689
56. Taniguchi E, Sakisaka S, Matsuo K, Tanikawa K, Sata M. Expression and role of vascular endothelial growth factor in liver regeneration after partial hepatectomy in rats. J Histochem Cytochem 2001; 49: 121-130
57. LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP, et al. Angiogenesis-independent endothelial protection of liver: role of VEGF-R1. Science 2003; 299: 890-893
58. Iguchi A, Kobayashi R, Yoshida M, Kobayashi K, Matsuo K, Kitajima I, et al. Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation. Bone Marrow Transplant 2001; 27: 1173-1180
59. Deleve LD, Wang X, Tsai J, Kanel G, Strasberg S, Tokes ZA. Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition. Gastroenterology 2003; 125: 882-890
60. nd G, Yang AD, Dallas NA, Gray MJ, Lim SJ, Xia L, et al. Effect of molecular therapeutics on liver regeneration in a murine model. J Clin Oncol 2008; 26: 1836-1842.
61. Barber FD, Mavligit G, Kurzrock R. Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview. Cancer Treat Rev 2004; 30: 425-436
62. Mocellin S, Pilati P, Lise M, Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 2007; 25: 5649-5654
63. Kemeny N, Jarnagin W, Paty P, Gonen M, Schwartz L, Morse M, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005; 23: 4888-4896
64. Shea Jr WJ, Demas BE, Goldberg HI, Hohn DC, Ferrell LD, Kerlan RK. Sclerosing cholangitis associated with hepatic arterial FUDR chemotherapy: radiographic-histologic correlation. AJR Am J Roentgenol 1986; 146: 717-721
65. Doria Jr MI, Shepard KV, Levin B, Riddell RH. Liver pathology following hepatic arterial infusion chemotherapy. Hepatic toxicity with FUDR. Cancer 1986; 58: 855-861
66. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 206: 685-693
67. Hohn DC, Stagg RJ, Friedman MA, Hannigan Jr JF, Rayner A, Ignoffo RJ, et al. A randomized trial of continuous intravenous versus hepatic intra-arterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989; 7: 1646-1654
68. Pulitano C, Arru M, Catena M, Guzzetti E, Vitali G, Ronzoni M, et al. Results of preoperative hepatic arterial infusion chemotherapy in patients undergoing liver resection for colorectal liver metastases. Ann Surg Oncol 2008; 15: 1661-1669
69. Tanaka K, Shimada H, Ueda M, Matsuo K, Endo I, Sekido H, et al. Perioperative complications after hepatectomy with or without intra-arterial chemotherapy for bilobar colorectal cancer liver metastases. Surgery 2006; 139: 599-607.
70. White RR, Schwartz LH, Munoz JA, Raggio G, Jarnagin WR, Fong Y, et al. Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases. J Surg Oncol 2008; 97: 601-604
71. Benoist S, Brouquet A, Penna C, Julie C, El Hajjam M, Chagnon S, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006; 24: 3939-3945
72. Welsh FK, Tilney HS, Tekkis PP, John TG, Rees M. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 2007; 96: 1037-1042
73. Cacheux W, Boisserie T, Staudacher L, Vignaux O, Dousset B, Soubrane O, et al. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann oncol 2008; 19: 1659-1661
74. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240: 1052-61; discussion 1061-1154